Developments in Psoriasis Management
Psoriasis (PsO) is a chronic inflammatory disease that can impact patients’ health-related quality of life.

- PsO is a chronic inflammatory disease with skin manifestations,\(^1,2\) thought to result from an uncontrolled immune response\(^1\).

- PsO has a substantial negative impact on patients’ emotional and social well-being\(^3,4\)
  - Itchy lesions\(^5\) and lesions affecting the soles,\(^6\) palms,\(^6\) nails,\(^7\) or scalp\(^8,9\) are particularly bothersome.

- Evidence suggests that psoriasis patients are at a higher risk for comorbidities such as obesity and heart disease,\(^10,11\) which can add to their overall disease burden.

\(~1.7\text{M patients in the United States have a diagnosis of moderate to severe PsO}\)\(^{12}\)

Patients May Avoid Treatment Due to Frustration

Although systemic treatments are effective in treating psoriasis,¹ many patients discontinue treatment because of dissatisfaction with existing therapies.²,*

* 57% and 45% discontinued oral therapies (n=820) and biologic therapies (n=389) respectively.
† The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey is the first large-scale multinational survey of the prevalence of psoriasis and psoriatic arthritis. It was based on samplings of households in the United States, Canada, France, Germany, Italy, Spain, and the United Kingdom; 3426 patients and 781 physicians were surveyed in North America and Europe.

In the MAPP survey, most patients whose lesions were ≥4 times the size of their palm reported being on no treatment or topical treatment only²,†

In a separate physician choice survey, dermatologists reported that 6 of 10 patients with moderate to severe psoriasis have never received systemic therapy, although an estimated 2/3 would benefit³,†

† Dermatology choice model survey assessing clinical decision drivers and activation levers in the treatment of psoriasis (N=151 dermatologists)

Reported Dissatisfaction With Available Treatment Options¹,*

* The MAPP survey is the first large-scale multinational survey of the prevalence of psoriasis and psoriatic arthritis. It was based on samplings of households in the United States, Canada, France, Germany, Italy, Spain, and the United Kingdom; 3426 patients and 781 physicians were surveyed in North America and Europe.

Real-World Analysis Revealed a Marked Increase in Healthcare Utilization and Costs

- A real-world analysis of US patients revealed that within 1 year of initiating biologic therapy, 25% of patients had completely discontinued treatment\(^1\),\(^*\)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Switchers</th>
<th>Non-switchers</th>
<th>Pure discontinuers</th>
<th>Re-Initiators: same therapy</th>
<th>Re-Initiators: different therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total healthcare costs per patient*</td>
<td>38,529 (24,328)</td>
<td>32,822 (15,913)</td>
<td>21,775 (25,483)</td>
<td>29,420 (18,287)</td>
<td>39,241 (29,266)</td>
</tr>
<tr>
<td>All-cause hospitalization cost</td>
<td>1,713 (12,529)</td>
<td>911 (4,663)</td>
<td>3,105 (14,425)</td>
<td>998 (7,024)</td>
<td>3,213 (14,342)</td>
</tr>
<tr>
<td>All-cause outpatient service cost*</td>
<td>6,562 (11,802)</td>
<td>4,622 (9,788)</td>
<td>6,723 (16,328)</td>
<td>4,802 (8,200)</td>
<td>11,222 (18,640)</td>
</tr>
<tr>
<td>All-cause ER visit cost*</td>
<td>447 (1301)</td>
<td>266 (1,001)</td>
<td>448 (1,3004)</td>
<td>310 (1,057)</td>
<td>1,206 (7,335)</td>
</tr>
<tr>
<td>All-cause physician office visit cost*</td>
<td>795 (522)</td>
<td>668 (558)</td>
<td>775 (918)</td>
<td>681 (538)</td>
<td>896 (701)</td>
</tr>
<tr>
<td>All medication cost*</td>
<td>30,303 (12,935)</td>
<td>27,313 (11,706)</td>
<td>12,061 (8,254)</td>
<td>23,619 (14,826)</td>
<td>24,837 (13,297)</td>
</tr>
<tr>
<td>Lab test cost</td>
<td>50 (282)</td>
<td>36 (298)</td>
<td>148 (850)</td>
<td>64 (1,153)</td>
<td>377 (2,047)</td>
</tr>
<tr>
<td>Radiotherapy cost</td>
<td>760 (5002)</td>
<td>415 (2,076)</td>
<td>1,180 (9,672)</td>
<td>411 (1,090)</td>
<td>941 (2,075)</td>
</tr>
</tbody>
</table>

* Retrospective claims database study, using data from the MarketScan® commercial and Medicare databases from October 2008 to March 2011. Patient inclusion criteria included primary psoriasis diagnosis (ICD-9 CM 696.1 or 696.8 codes). Claims databases do not provide any information regarding the underlying reasons for therapy changes or discontinuations. Cost in US dollars, mean (standard deviation); \(P<.05\) for switchers compared with non-switchers.

The average cost to plans from patients who discontinued biologic therapy was $21,775 annually

With an ongoing commitment to delivering innovative therapies for patients living with inflammatory and immunologic diseases, Celgene is focused on understanding psoriasis and the activity of novel disease targets.
Thank You!